Low Molecular Weight Heparin Market - Size, Share, Outlook, and Opportunity Anal
Posted by Rajkumar on June 28th, 2019
Low Molecular Weight Heparins (LMWH) are a form of pharmacological anticoagulant intervention which are derived from UFH by chemical or enzymatic depolymerisation to yield fragments that are around one third the size of heparin. Low molecular weight heparin is used for prophylaxis of deep vein thrombosis and pulmonary embolism, or thrombosis occurring in a broad spectrum of clinical indications, including general or orthopaedic surgery, neurosurgery, trauma, unstable angina, and myocardial infarction. LMWHs are However, it is associated with higher anticoagulant effect and provides higher bioavailability after subcutaneous administration, as compared to unfractionated heparin (UFH), for thromboembolic indications. Low molecular weight heparin is the most suitable anticoagulant in case of complicated pregnancy, as it eliminates risk of crossing the placental membrane.
Browse Complete Report For More Information @ http://bit.ly/2JeLsJq
The global low molecular weight heparin market size was valued at US$ 2,882.6 Mn in 2017, and is expected to witness a CAGR of 6.7% during the forecast period (2018 – 2026).
Increasing Advantages of Low Molecular Weight Heparin over Unfractionated Heparin is expected to drive the Market Growthduring the Forecast Period
Unfractionated heparin or standard heparin varies in action from patient to patient. Thus, it can only be administered to hospitalized patients under monitoring, while low molecular weight heparins (LMWHs) can be used subcutaneously once a day, without requirement for monitoring.
Furthermore, LMWHs have more predictable pharmacokinetic properties as compared to unfractionated heparin (UFH), which allows LMWHs to be administered in fixed doses and without the need for dose adjustment based on laboratory monitoring.
Increasing number of people are being affected with Deep Vein Thrombosis (DVT) which will subsequently increase demand for LMWH. For instance, according to National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention (CDC), February 2018; the precise number of people affected by DVT/PE is unknown, although as many as 900,000 people could be affected (1 to 2 per 1,000) each year in the U.S.
Furthermore, increasing engagement of government healthcare regulatory bodies in developing and delivering effective and cost-effective low molecular weight heparin molecule products in the market is expected to propel the growth of the market. For instance, in 2014, American Society of Health-System Pharmacists (ASHP) issued the policy for safe and effective use of heparin in neonatal patients thereby supporting the development and use of nationally standardized concentrations of heparin when used for maintenance and flush of peripheral and central venous lines in neonatal patients.
Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1491
Key players operating in the low molecular weight heparin market include, Pfizer, Inc., LEO Pharma A/S, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, Changzhou Qianhong Biopharma, and Intrapharm Laboratories.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Like it? Share it!
About the AuthorRajkumar
Joined: February 13th, 2019
Articles Posted: 590
More by this author